148 related articles for article (PubMed ID: 30310317)
1. Galectin-3 and β-catenin are associated with a poor prognosis in serous epithelial ovarian cancer.
Liu Y; Xie L; Wang D; Li D; Xu G; Wang L; Zhou H; Yu Y; Lin Z; Lu H
Cancer Manag Res; 2018; 10():3963-3971. PubMed ID: 30310317
[TBL] [Abstract][Full Text] [Related]
2. Comparison of advanced stage mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and survival outcome: a matched case-control study.
Karabuk E; Kose MF; Hizli D; Taşkin S; Karadağ B; Turan T; Boran N; Ozfuttu A; Ortaç UF
J Gynecol Oncol; 2013 Apr; 24(2):160-6. PubMed ID: 23653834
[TBL] [Abstract][Full Text] [Related]
3. Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer.
Bodnar L; Stanczak A; Cierniak S; Smoter M; Cichowicz M; Kozlowski W; Szczylik C; Wieczorek M; Lamparska-Przybysz M
J Ovarian Res; 2014 Feb; 7():16. PubMed ID: 24499657
[TBL] [Abstract][Full Text] [Related]
4. Expression and clinical significance of Gal-3 and NFκB pathway-related factors in epithelial ovarian carcinoma.
Luk HM; Wang DY; Xie LL; Liu XY; Xu GC; Lu HW
Int J Clin Exp Pathol; 2020; 13(5):1197-1205. PubMed ID: 32509095
[TBL] [Abstract][Full Text] [Related]
5. Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling Pathway.
Liao Y; Badmann S; Kaltofen T; Mayr D; Schmoeckel E; Deuster E; Mannewitz M; Landgrebe S; Kolben T; Hester A; Beyer S; Burges A; Mahner S; Jeschke U; Trillsch F; Czogalla B
Biomedicines; 2021 Jun; 9(7):. PubMed ID: 34206491
[TBL] [Abstract][Full Text] [Related]
6. Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma.
Maftouh M; Belo AI; Avan A; Funel N; Peters GJ; Giovannetti E; Van Die I
Oncotarget; 2014 Jul; 5(14):5335-49. PubMed ID: 24977327
[TBL] [Abstract][Full Text] [Related]
7. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
8. Comparison of early-stage primary serous fallopian tube carcinomas and equivalent stage serous epithelial ovarian carcinomas.
Horng HC; Lai CR; Chang WH; Wen KC; Chen YJ; Juang CM; Yen MS; Wang PH
Taiwan J Obstet Gynecol; 2014 Dec; 53(4):547-51. PubMed ID: 25510699
[TBL] [Abstract][Full Text] [Related]
9. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
10. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer.
Kan CW; Hahn MA; Gard GB; Maidens J; Huh JY; Marsh DJ; Howell VM
BMC Cancer; 2012 Dec; 12():627. PubMed ID: 23272653
[TBL] [Abstract][Full Text] [Related]
11. Nuclear β-catenin positivity as a predictive marker of long-term survival in advanced epithelial ovarian cancer.
Nagy B; Tóth L; Molnár P; Méhes G; Thurzó L; Póka R; Hernádi Z
Pathol Res Pract; 2017 Aug; 213(8):915-921. PubMed ID: 28651933
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of long noncoding RNA HOXB-AS3 indicates an unfavorable prognosis and promotes tumorigenesis in epithelial ovarian cancer via Wnt/β-catenin signaling pathway.
Zhuang XH; Liu Y; Li JL
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31337688
[TBL] [Abstract][Full Text] [Related]
13. Galectin-1 promotes tumor progression via NF-κB signaling pathway in epithelial ovarian cancer.
Chen L; Yao Y; Sun L; Tang J
J Cancer; 2017; 8(18):3733-3741. PubMed ID: 29151961
[No Abstract] [Full Text] [Related]
14. Prognostic Significance of Lymph Node Ratio in Ovarian Cancer.
Tong X; Li H; Chen H; Zhai D; Pang Y; Lin R; Xu Y
Open Med (Wars); 2019; 14():279-286. PubMed ID: 30886899
[TBL] [Abstract][Full Text] [Related]
15. BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.
Sallum LF; Andrade L; Bastos Eloy da Costa L; Ramalho S; Ferracini AC; Natal RA; Brito ABC; Sarian LO; Derchain S
Int J Gynecol Cancer; 2018 Mar; 28(3):437-447. PubMed ID: 29465506
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of β-catenin and cyclinD1 predicts a poor prognosis in ovarian serous carcinomas.
Wang H; Wang H; Makki MS; Wen J; Dai Y; Shi Q; Liu Q; Zhou X; Wang J
Int J Clin Exp Pathol; 2014; 7(1):264-71. PubMed ID: 24427347
[TBL] [Abstract][Full Text] [Related]
17. Comparison Of Early-Stage High-Grade Serous Primary Fallopian Tube Cancers and Epithelial Ovarian Cancers: A Multicenter Study.
Gungorduk K; Ozdemir A; Selcuk I; Telli E; Şahin Ö; Toptaş T; Akman L; Güzel AB; Taşkın S; Öge T; Güngördük Ö; Gokçü M; Gungor T; Yaşar L; Terek MC; Ozan H; Ozsaran A; Sancı M; Vardar MA; Meydanlı MM; Yalçın ÖT; Ortac F; Özalp S
Oncol Res Treat; 2017; 40(4):203-206. PubMed ID: 28376498
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-200c and microRNA-31 regulate proliferation, colony formation, migration and invasion in serous ovarian cancer.
Ibrahim FF; Jamal R; Syafruddin SE; Ab Mutalib NS; Saidin S; MdZin RR; Hossain Mollah MM; Mokhtar NM
J Ovarian Res; 2015 Aug; 8():56. PubMed ID: 26260454
[TBL] [Abstract][Full Text] [Related]
19. Microarray expression identification of differentially expressed genes in serous epithelial ovarian cancer compared with bulk normal ovarian tissue and ovarian surface scrapings.
Grisaru D; Hauspy J; Prasad M; Albert M; Murphy KJ; Covens A; Macgregor PF; Rosen B
Oncol Rep; 2007 Dec; 18(6):1347-56. PubMed ID: 17982616
[TBL] [Abstract][Full Text] [Related]
20. Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer.
Kwon M; Kim JH; Rybak Y; Luna A; Choi CH; Chung JY; Hewitt SM; Adem A; Tubridy E; Lin J; Libutti SK
Oncotarget; 2016 Nov; 7(47):77052-77070. PubMed ID: 27776341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
